ACR 2026 at a glance
The ACR 2026 Annual Meeting will highlight developments in rheumatology that could reshape treatment strategies, clinical differentiation and competitive positioning. From deeper immune depletion and CAR-T therapy to head-to-head trials and AI reliability, emerging evidence will raise important questions about durability, safety, access and clinical adoption.
LucidQuest is monitoring the scientific developments and competitor signals that could influence the next phase of rheumatology treatment.
📅 Build your schedule around the sessions that matter most.
📥 Download the ACR_2026_Preview_by_LucidQuest
Key Scientific and Strategic Themes at ACR 2026
Cellular Therapy: CAR-T in Refractory Lupus
CAR-T data in refractory lupus will shift attention toward durable responses, programme readiness, safety and access.
B-Cell Depletion: Obinutuzumab, BAFF/APRIL and T-Cell Engagers
Obinutuzumab, BAFF/APRIL-directed agents and T-cell engagers may redefine expectations for depth and durability of remission.
Sjögren’s Disease: Emerging Mechanisms and Registrational Strategies
Emerging mechanisms, evolving endpoints and growing pipeline competition could reshape registrational strategies.
Immunometabolic Medicine: Retatrutide in Knee Osteoarthritis
Phase 3 retatrutide data in knee osteoarthritis may strengthen the case for targeting obesity as a disease driver.
Head-to-Head Competition: Bimekizumab Versus Risankizumab
Bimekizumab versus risankizumab and oral targeted therapy comparisons could reset differentiation benchmarks.
Competitor and Industry Signals
Bristol Myers Squibb and Cabaletta Bio: CAR-T Durability and Safety in Lupus
Zola-cel and rese-cel readouts will provide further evidence on CAR-T durability and safety in refractory lupus.
Novartis and Amgen: Sjögren’s Disease Treatment Competition
Ianalumab and dazodalibep data will inform competitive positioning in Sjögren’s disease.
UCB and Johnson & Johnson: Psoriatic Arthritis Treatment Differentiation
Psoriatic arthritis programmes will highlight superiority evidence, axial involvement and treatment differentiation.
argenx and CDR-Life: Expanding Modality Competition in Myositis
Phase 3 ALKIVIA results in myositis and CDR209 development signal expanding modality competition.
Artificial Intelligence and Machine Learning at ACR 2026
AI Reliability: Guideline Concordance and Hallucination Risk
Guideline concordance and hallucination-risk comparisons will test clinical trustworthiness.
AI-Enabled Discovery: Spatial Multiomics and Interpretable Machine Learning
Spatial multiomics, interpretable ML and AI-supported trials could advance target discovery, patient selection and endpoint design.
What We Are Watching After ACR 2026
- Whether CAR-T can progress into scalable clinical pathways.
- Whether deeper B-cell depletion delivers durable, organ-level remission.
- Whether Sjögren’s endpoints can support registrational trials.
- Whether AI tools demonstrate sufficient reliability for clinical adoption.
Download the LucidQuest ACR 2026 Preview Report
Which emerging rheumatology therapies could redefine clinical outcomes and competitive positioning at ACR 2026? Download LucidQuest’s ACR 2026 preview report to explore the key scientific developments, therapeutic advances and competitor signals we are watching ahead of the conference.
📅 Build your schedule around the sessions that matter most.
📥 Download the ACR_2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
